KCNA6

Potassium voltage-gated channel subfamily A member 6 · P17658 · KCNA6 on Sugi Atlas →

386 patent compounds predicted against KCNA6, 301 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL13036733	1.00	9/20
Oroidin (SCHEMBL13036738)	1.00	9/20
Oroidin (SCHEMBL13036750)	1.00	9/20
SCHEMBL21182348	1.00	9/20
SCHEMBL13074094	0.74	9/20
SCHEMBL13036735	0.67	9/20
Clathrodin (SCHEMBL13036737)	0.67	9/20
Clathrodin (SCHEMBL13036741)	0.67	9/20
Oroidin (SCHEMBL12597862)	0.65	9/20
Oroidin (SCHEMBL14536687)	0.65	9/20
Oroidin (SCHEMBL28891358)	0.65	9/20
SCHEMBL31722801	0.64	9/20
Keramadine (SCHEMBL11123414)	0.64	9/20
Keramadine (SCHEMBL11123417)	0.64	9/20
SCHEMBL13036715	0.61	9/20
SCHEMBL13074314	0.52	9/20
SCHEMBL13074223	0.47	9/20
Hydrochloric Acid (SCHEMBL30045379)	0.55	4/20
SCHEMBL15228546	0.57	3/20
SCHEMBL15232609	0.57	3/20

Clinical trials — most relevant to KCNA6 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery	PHASE4	RECRUITING
Long-Term Sulfonylurea Response in ABCC8 Neonatal Diabetes (SuResponsSUR)	PHASE4	UNKNOWN
Long-Term Sulfonylurea Response in KCNJ11 Neonatal Diabetes	PHASE4	COMPLETED
Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease	PHASE4	NOT_YET_RECRUITING
Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study	PHASE4	COMPLETED
Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study	PHASE3	COMPLETED
Mutation-specific Therapy for the Long QT Syndrome	PHASE2	COMPLETED
Sandostatine® LP and Hyperinsulinism	PHASE2	COMPLETED
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients	PHASE2	COMPLETED
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy	PHASE1/PHASE2	RECRUITING
Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss	PHASE2	COMPLETED
Evaluating Possible Improvement in Tinnitus Severity After 28 Days Dosing of the Study Drug AUT00063 Compared to Placebo	PHASE2	COMPLETED
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK	PHASE1	COMPLETED
Peripheral KV7 Activation for Pain Relief	EARLY_PHASE1	COMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism	nan	COMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Qatar Cardiovascular Biorepository of AF Patients	nan	UNKNOWN
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.	nan	UNKNOWN
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy	nan	UNKNOWN
The Effects of the Anesthetic Drug Propofol on the Way the Heart Recovers Between Beats	nan	COMPLETED
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation	nan	UNKNOWN
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA)	nan	UNKNOWN
The Effects of the Anti Nausea Drugs Droperidol and Ondansetron on the Way the Heart Recovers Between Beats	nan	COMPLETED
Metabolism of Patients With Genetically Caused Cardiac Arrhythmia	nan	UNKNOWN
Characteristics of Episodic Ataxia Syndrome	nan	COMPLETED
Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome	nan	RECRUITING
Sodium Channel Splicing in Heart Failure Trial	nan	COMPLETED
Characteristics of Andersen-Tawil Syndrome	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a KCNA6 binder may also engage these)

Protein	Name	Similarity
P17659	—	1.000	P17659 →
P19024	—	1.000	P19024 →
Q61923	—	1.000	Q61923 →
Q61762	—	1.000	Q61762 →
P50638	—	1.000	P50638 →
KCNA5	Potassium voltage-gated channel subfamily A member 5	1.000	landscape →
P16390	—	0.997	P16390 →
P15384	—	0.996	P15384 →
KCNA2	Potassium voltage-gated channel subfamily A member 2	0.995	landscape →
P79197	—	0.995	P79197 →
P25122	—	0.995	P25122 →
Q63734	—	0.994	Q63734 →
P22739	—	0.994	P22739 →
Q96PR1	—	0.994	Q96PR1 →
Q03721	—	0.992	Q03721 →
A4K2P6	—	0.992	A4K2P6 →
P63142	—	0.991	P63142 →
P63141	—	0.991	P63141 →
Q8TDN2	—	0.991	Q8TDN2 →
Q28293	—	0.991	Q28293 →
KCNA3	Potassium voltage-gated channel subfamily A member 3	0.991	landscape →
A4K2M4	—	0.991	A4K2M4 →
P22462	—	0.990	P22462 →
Q28527	—	0.990	Q28527 →
Q61423	—	0.990	Q61423 →
Q17ST2	—	0.990	Q17ST2 →
KCNC1	Voltage-gated potassium channel KCNC1	0.990	landscape →
P15385	—	0.990	P15385 →
Q03719	—	0.989	Q03719 →
P15388	—	0.989	P15388 →